News Quantified

EDSA – edesa biotech, inc. - common shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Edesa Biotech GAAP EPS of -$1.27 beats by $0.51 [Seeking Alpha]

Edesa Biotech Reports Fiscal Year 2025 Results [Canadian Business Journal (Canada)]

Edesa Biotech Reports Fiscal Year 2025 Results

Edesa Biotech (NASDAQ:EDSA) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Edesa Biotech (NASDAQ:EDSA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.

Form 8-K Edesa Biotech, Inc. For: Dec 12

Form 424B5 Edesa Biotech, Inc.

Form 10-K Edesa Biotech, Inc. For: Sep 30

Form 8-K Edesa Biotech, Inc. For: Dec 12

Form 4 Edesa Biotech, Inc. For: Dec 01 Filed by: Nijhawan Pardeep

Top News Gainers

9/5 Edesa Biotech Receives Approval to Initiate Clinical Study in Patients with Hemorrhoids 44.1%

3/19 Form 4 Edesa Biotech, Inc. For: Mar 17 Filed by: Nijhawan Pardeep 19.3%

9/10 Form SC 13D/A Edesa Biotech, Inc. Filed by: 10379085 Canada Inc. 13.6%

7/25 Edesa Biotech Completes Manufacturing for Upcoming Dermatitis Study 12.9%

2/14 Form 4 Edesa Biotech, Inc. For: Feb 12 Filed by: OAKES FRANK R. 11.0%

1/10 Form 4 Edesa Biotech, Inc. For: Jan 08 Filed by: Brooks Michael J 11.0%

7/10 Edesa Biotech Pushes Forward To Phase 2b Study For Lead Clinical Product [Seeking Alpha] 10.6%

8/29 Edesa Biotech to Present at H. C. Wainwright Global Investment Conference 10.6%

3/23 Form DEF 14A Edesa Biotech, Inc. For: May 13 8.1%

9/13 Form EFFECT Edesa Biotech, Inc. 7.6%

Top News Decliners

3/12 Edesa Biotech to Develop Novel Treatment for Vitiligo in Collaboration with the National Research Council of Canada -19.6%

1/6 Edesa Biotech Announces $4.36 million Registered Direct Offering -19.5%

6/20 Form 8-K/A Edesa Biotech, Inc. For: Jun 07 -18.1%

6/11 Form 3 Edesa Biotech, Inc. For: Jun 07 Filed by: Nijhawan Pardeep -13.5%

3/9 Form EFFECT Edesa Biotech, Inc. -12.2%

1/10 Form 4 Edesa Biotech, Inc. For: Jan 08 Filed by: Pay Paul William -10.4%

8/14 Form 8-K Edesa Biotech, Inc. For: Aug 14 -9.2%

4/20 Edesa Biotech in-licenses two COVID-19 candidates; shares up 21% [Seeking Alpha] -8.9%

2/25 Form S-1 Edesa Biotech, Inc. -8.0%

3/30 Edesa Biotech (NASDAQ: EDSA) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a price target on the stock. -6.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day